Eton Pharmaceuticals Inc. (ETON) to Resume Trading at 11:10 a.m.

Go back to Eton Pharmaceuticals Inc. (ETON) to Resume Trading at 11:10 a.m.

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

June 15, 2021 10:38 AM EDT

DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products, said Sean Brynjelsen, CEO of Eton Pharmaceuticals. This innovative... More